Solara Active Pharma Sciences Ltd. (SOLARA) Share Price Rises 8.05% Today

Solara Active Pharma Sciences Ltd. traded at Rs 550.20, up 8.05% today, taking its market capitalisation to Rs 2,465.73 crore and placing it among notable small-cap gainers.

Solara Active Pharma Sciences Ltd. Share Price moved higher to Rs 550.20 on 18 August 2026, up Rs 41.00 or 8.05% from the previous close of Rs 509.20, lifting the company’s market capitalisation to Rs 2,465.73 crore. In today’s Stock Market Today setup, that made the counter one of the more visible Stocks in News from the pharmaceuticals space and a confirmed top gainer under the workflow’s price rise threshold screen for the Small Cap category.

The supplied data confirms the price event clearly: the stock opened at Rs 506.80, touched an intraday high of Rs 555.00 and did not break below its opening level, with the day’s low also at Rs 506.80. That intraday profile points to sustained buying support after the opening print rather than a brief spike. Turnover stood at Rs 1.60 crore on the exchange volume field used for the event, while total traded volume across exchanges reached 7,02,088 shares.

For readers searching Solara Active Pharma Sciences Ltd. Share Price Today, Solara Active Pharma Sciences Ltd. Stock News or Why Solara Active Pharma Sciences Ltd. is Rising Today, the verified data establishes the share price gain and the strong day’s move, but it does not establish a company-specific catalyst. What investors can monitor next is whether this price rise continues to attract volume, how the stock’s valuation compares with the Healthcare and Pharmaceuticals & Drugs benchmark, and whether profitability ratios continue to support attention. Univest therefore treats today’s move as a data-backed price action event first, and a broader stock analysis question second.

Solara Active Pharma Sciences Ltd. (SOLARA) Share Price Today: Price Action Analysis

Solara Active Pharma Sciences Ltd. (SOLARA) traded at Rs 550.2. versus the previous close of Rs 509.2, a rise of 8.05%. The stock opened at Rs 506.8, reached Rs 555, touched Rs 506.8. Reported volume was 29,150.

Solara Active Pharma Sciences Ltd. (SOLARA) Fundamental Analysis

Solara Active Pharma Sciences Ltd. was valued at a P/E ratio of -1,618.24x, a P/B ratio of 1.93x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 17.23% and ROCE of 15.34%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs -0.34, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Solara Active Pharma Sciences Ltd. Share Price is now being watched more closely because the valuation and profitability picture is not straightforward. The company’s market capitalisation stands at Rs 2,465.73 crore, placing it in the small-cap bracket by the supplied classification, while the broader industry benchmark shows 136 companies in the same Pharmaceuticals & Drugs universe. Market cap indicates size, not quality, so investors need to look deeper at the ratio profile behind today’s move.

The most striking figure is the P/E ratio of -1618.24. A negative P/E generally reflects negative trailing earnings, and that fits with the supplied EPS of -0.34. In simple terms, EPS shows earnings attributable to each share, and the current figure indicates a loss on that trailing basis. That is why this Solara Active Pharma Sciences Ltd. Fundamental Analysis cannot rely on P/E as a standard valuation shorthand. Against the same-industry benchmark, the median P/E is 26.24, the average is 39.98, the minimum is 2.96 and the maximum is 359.13 across 105 companies with available P/E data. Because the company’s P/E is negative, it sits outside the usual positive valuation band of the peer set.

The P/B ratio, however, is 1.93, which is much easier to compare. That is slightly above the industry median P/B of 1.82 but below the industry average of 2.49 across 135 companies. On that measure, Solara does not screen as an extreme outlier. Profitability metrics are more encouraging: ROE is 17.23% versus the industry median of 10.49% and average of 8.10%, while ROCE is 15.34% versus the median of 12.97% and very close to the average of 15.53%. Those figures suggest that despite the negative trailing EPS, the company’s return ratios are better than many sector names on the supplied benchmark set.

Dividend yield is 0, which means the stock is not currently offering a historical yield cushion in the supplied data. That makes price action, profitability quality and valuation context even more relevant for investors tracking Solara Active Pharma Sciences Ltd. Share Price. In Univest’s reading, the fundamentals offer a mixed but interesting backdrop: a negative earnings multiple and negative EPS on one side, balanced against better-than-benchmark ROE and a near-benchmark ROCE on the other. That sets up an important comparison with sector norms and listed peers.

Sector and Industry Context

Solara Active Pharma Sciences Ltd. (SOLARA) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Solara Active Pharma Sciences Ltd. (SOLARA) has a P/E ratio of -1,618.24x, which is below the benchmark median of 26.24x, a difference of -6,267.07%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Solara Active Pharma Sciences Ltd. (SOLARA) has a ROE of 17.23%, which is above the benchmark median of 10.49%, a difference of +64.25%. Solara Active Pharma Sciences Ltd. (SOLARA) has a ROCE of 15.34%, which is above the benchmark median of 12.97%, a difference of +18.27%.

Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Solara Active Pharma Sciences Ltd. Share Price is best understood in the context of the Healthcare sector and the Pharmaceuticals & Drugs industry, where the supplied benchmark covers 136 companies in the same industry. Relative to that group, Solara sits well above the median company by market capitalisation, trades near the middle on price-to-book, and shows return ratios that are stronger than several benchmark reference points.

The market-cap comparison is one of the clearest contextual markers. Solara’s market capitalisation of Rs 2,465.73 crore is far above the benchmark median of Rs 142.37 crore and also comfortably above the benchmark average of Rs 492.43 crore. The industry’s minimum market cap in the supplied set is Rs 6.06 crore, while the maximum is Rs 2,985.15 crore. That places Solara toward the upper end of this same-industry universe by size, though still classified as Small Cap in the event feed.

Valuation is more nuanced. Solara’s company P/E is -1618.24, while the industry median is 26.24 and the average is 39.98. Because the company’s P/E is negative, it is not directly comparable to the positive range running from 2.96 to 359.13 for the 105 benchmark companies with available P/E figures. By contrast, the company P/B of 1.93 sits close to the benchmark median of 1.82 and below the average of 2.49, inside a broad industry range of -11.02 to 16.76 across 135 companies.

On profitability, Solara’s ROE of 17.23% is above both the benchmark median of 10.49% and average of 8.10%. ROCE of 15.34% is above the median of 12.97% and only marginally below the average of 15.53%. That combination suggests the Solara Active Pharma Sciences Ltd. Share Price rise came from a stock whose return profile is better than many same-industry names, even though the earnings multiple remains distorted by negative trailing EPS. For investors following Share Market Today and Top Gainers Today, that mixed valuation-versus-profitability backdrop is a key part of the story.

Peer Comparison

Solara Active Pharma Sciences Ltd. (SOLARA) has a P/E ratio of -1,618.24x compared with the displayed peer median of 54.85x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 17.23% compares with a peer median of 11.42% across the companies shown in the table. ROCE stood at 15.34% versus the displayed peer median of 13.15%, providing a capital-efficiency comparison. Solara Active Pharma Sciences Ltd. (SOLARA) has a market capitalisation of Rs 2,465.73 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Solara Active Pharma Sciences Ltd. Share Price also becomes more meaningful when placed beside nearby listed peers in Pharmaceuticals & Drugs. By market capitalisation, Solara at Rs 2,465.73 crore sits below Dishman Carbogen Amcis Ltd. at Rs 2,985.15 crore, Beta Drugs Ltd. at Rs 2,827.67 crore, Hikal Ltd. at Rs 2,686.72 crore, Ind-Swift Laboratories Ltd. at Rs 2,645.37 crore and Fredun Pharmaceuticals Ltd. at Rs 2,559.68 crore, but above Sai Parenteral’s Ltd. at Rs 2,438.25 crore, Panacea Biotec Ltd. at Rs 2,429.20 crore, Venus Remedies Ltd. at Rs 2,388.41 crore and NGL Fine-Chem Ltd. at Rs 2,139.20 crore. That positions the company near the upper cluster of its peer set by size.

On valuation, the comparison is unusual because Solara’s P/E is -1618.24, while peers with available P/E data include Dishman Carbogen Amcis at 170.32, Beta Drugs at 65.02, Ind-Swift Laboratories at 47.53, Fredun Pharmaceuticals at 54.85, Sai Parenteral’s at 170.53, Venus Remedies at 20.48 and NGL Fine-Chem at 31.64. A negative P/E means the stock cannot be lined up conventionally against those positive multiples. Its P/B of 1.93 is, however, below Beta Drugs at 10.29, Fredun at 8.19, NGL Fine-Chem at 5.21, Venus Remedies at 3.47 and Sai Parenteral’s at 3.12, close to Hikal at 2.20 and Ind-Swift at 1.82, and above Dishman Carbogen Amcis at 0.42.

Return ratios show a firmer picture. Solara’s ROE of 17.23% is above Hikal at 15.22%, Fredun at 11.42%, Sai Parenteral’s at 13.90%, Panacea Biotec at 0, Venus Remedies at 9.85%, Ind-Swift at -0.78% and Dishman Carbogen Amcis at -2.89%, though below Beta Drugs at 18.65% and NGL Fine-Chem at 27.90%. Its ROCE of 15.34% is above Fredun at 13.15%, Sai Parenteral’s at 12.97%, Panacea at 5.36%, Venus at 7.89%, Ind-Swift at 8.31% and Dishman at -0.26%, but below Hikal at 16.15%, Beta Drugs at 22.17% and NGL Fine-Chem at 33.91%. The peer set therefore shows a company with competitive profitability ratios, even though the earnings multiple remains an outlier.

Why Investors Are Watching Solara Active Pharma Sciences Ltd.

Solara Active Pharma Sciences Ltd. Share Price is on watch because today’s move combines a clear single-day price rise with a market-cap size that makes it stand out within the listed Pharmaceuticals & Drugs basket. The stock also sits close to the upper end of its peer group by size, while its P/B, ROE and ROCE readings give investors a more balanced picture than the negative P/E alone would suggest.

• Verified price action: the stock rose 8.05% to Rs 550.20 from Rs 509.20, after opening at Rs 506.80 and touching Rs 555.00.
• Volume participation: total volume reached 7,02,088 shares, with 6,72,938 on NSE and 29,150 on BSE, while BSE turnover stood at Rs 1.60 crore.
• Fundamental context: P/E is -1618.24, P/B is 1.93, ROE is 17.23%, ROCE is 15.34%, EPS is -0.34 and dividend yield is 0.
• Sector positioning: market cap of Rs 2,465.73 crore is above the industry average and median in the supplied same-industry benchmark.
• Peer perspective: profitability compares favourably with several nearby pharma names, even as the earnings multiple remains atypical.

What investors may monitor next is whether Solara Active Pharma Sciences Ltd. Share Price holds near the upper end of today’s range, whether trading interest remains elevated across NSE and BSE, and whether future financial updates bring better alignment between EPS and the otherwise solid ROE and ROCE profile. Univest views those as the most relevant follow-through indicators after today’s rally.

About Solara Active Pharma Sciences Ltd.

Solara Active Pharma Sciences Ltd. is tracked in the Healthcare sector and the Pharmaceuticals & Drugs industry in the supplied market dataset. That places the company in a large and diverse listed universe of 136 same-industry companies used for the benchmark comparison in this article. Within that universe, Solara’s market capitalisation of Rs 2,465.73 crore puts it toward the larger end of the group, even though the event engine classifies it as a Small Cap for screening purposes.

For readers looking for Solara Active Pharma Sciences Ltd. Stock News, company context matters because industry comparisons often shape how investors interpret a strong one-day move. In the supplied peer basket, Solara sits near companies such as Dishman Carbogen Amcis, Beta Drugs, Hikal, Ind-Swift Laboratories, Fredun Pharmaceuticals, Sai Parenteral’s, Panacea Biotec, Venus Remedies and NGL Fine-Chem. That gives the market a relevant comparison set for valuation, return ratios and market-cap positioning.

Because the verified dataset for this article is focused on market and financial metrics rather than a full business profile, the most reliable company overview comes from its sector and industry placement. In practical terms, Solara is being assessed by the market alongside other listed Pharmaceuticals & Drugs businesses, where investors commonly focus on Share Price, profitability ratios, valuation multiples and relative scale. That is why today’s Solara Active Pharma Sciences Ltd. Share Price rise is being read not just as a trading move, but also as a comparative event within healthcare stocks.

Track Solara Active Pharma Sciences Ltd. Share Price on Univest

Use Solara Active Pharma Sciences Ltd. (SOLARA) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors who want to follow Solara Active Pharma Sciences Ltd. Share Price more closely can use Univest to track live share price moves, day change, market capitalisation trends and broader Stock News in one place. Univest also helps users compare valuation ratios such as P/E and P/B, monitor profitability markers like ROE and ROCE, review 52-week levels when available, and study how a stock sits against industry benchmarks and peers.

For anyone researching Solara Active Pharma Sciences Ltd. Share Price Today, Solara Active Pharma Sciences Ltd. Share News or a broader Solara Active Pharma Sciences Ltd. Stock Analysis, the platform context matters because single-day price rises are more useful when read alongside financial ratios, peer positioning and sector data. Univest therefore frames today’s move as a factual market update supported by comparative analytics, not as a prediction or recommendation.

Frequently Asked Questions

Why did Solara Active Pharma Sciences Ltd. Share Price rise today?

Ans. The supplied data confirms that Solara Active Pharma Sciences Ltd. Share Price rose 8.05% to Rs 550.20 from Rs 509.20. It establishes the price event and volume participation, but it does not identify any verified company-specific catalyst.

What was Solara Active Pharma Sciences Ltd. Share Price Today?

Ans. Solara Active Pharma Sciences Ltd. Share Price Today was Rs 550.20 at the event timestamp. The stock gained Rs 41.00 during the session, after opening at Rs 506.80 and touching an intraday high of Rs 555.00.

How much did SOLARA gain in today’s trade?

Ans. SOLARA gained 8.05% in today’s session, equivalent to a rise of Rs 41.00 over the previous close of Rs 509.20. That move placed the stock among notable small-cap gainers in today’s market action.

What do today’s high, low and open show for the stock?

Ans. The stock opened at Rs 506.80, which was also the day’s low, and later climbed to Rs 555.00. That pattern shows the session moved upward after the open, with the price staying above the initial level.

What was the traded volume in Solara Active Pharma Sciences Ltd. today?

Ans. Total traded volume was 7,02,088 shares, including 6,72,938 shares on NSE and 29,150 shares on BSE. The event feed also recorded BSE turnover of Rs 1.60 crore, indicating active exchange participation.

What is the market capitalisation of Solara Active Pharma Sciences Ltd.?

Ans. The company’s market capitalisation stood at Rs 2,465.73 crore in the supplied data. The event engine classified the stock in the Small Cap category, while the same-industry benchmark shows it above sector median size.

Is Solara Active Pharma Sciences Ltd. expensive compared with its industry?

Ans. The P/E ratio is -1618.24, so it is not directly comparable with the industry median P/E of 26.24 or average of 39.98. Its P/B ratio of 1.93 is closer to the benchmark median of 1.82.

How do Solara’s profitability ratios compare with the sector benchmark?

Ans. Solara’s ROE is 17.23%, above the industry median of 10.49% and average of 8.10%. Its ROCE is 15.34%, above the median of 12.97% and very close to the benchmark average of 15.53%.

What does EPS and dividend yield indicate for Solara?

Ans. The supplied EPS is -0.34, which indicates negative trailing earnings per share and helps explain the negative P/E ratio. Dividend yield is 0, so the current dataset does not show any historical yield support.

Which sector and industry does Solara Active Pharma Sciences Ltd. belong to?

Ans. Solara Active Pharma Sciences Ltd. is classified under the Healthcare sector and Pharmaceuticals & Drugs industry. The benchmark used in this article covers 136 companies from the same industry for valuation and profitability comparison.